OssDsign Valuation
Is OSSD undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of OSSD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate OSSD's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate OSSD's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for OSSD?
Other financial metrics that can be useful for relative valuation.
What is OSSD's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | SEK 863.30m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 6.2x |
Enterprise Value/EBITDA | -10.6x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does OSSD's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 10.1x | ||
BACTI B Bactiguard Holding | 11.4x | 12.6% | SEK 2.4b |
XVIVO Xvivo Perfusion | 22.2x | 26.7% | SEK 15.5b |
IMS Invent Medic Sweden | 4.9x | n/a | SEK 32.9m |
BIOWKS Bio-Works Technologies | 2x | n/a | SEK 81.5m |
OSSD OssDsign | 7.3x | 23.9% | SEK 863.3m |
Price-To-Sales vs Peers: OSSD is good value based on its Price-To-Sales Ratio (7.3x) compared to the peer average (10.1x).
Price to Earnings Ratio vs Industry
How does OSSD's PE Ratio compare vs other companies in the SE Medical Equipment Industry?
Price-To-Sales vs Industry: OSSD is expensive based on its Price-To-Sales Ratio (7.3x) compared to the Swedish Medical Equipment industry average (5.2x).
Price to Sales Ratio vs Fair Ratio
What is OSSD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 7.3x |
Fair PS Ratio | 6.8x |
Price-To-Sales vs Fair Ratio: OSSD is expensive based on its Price-To-Sales Ratio (7.3x) compared to the estimated Fair Price-To-Sales Ratio (6.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | SEK 8.50 | SEK 13.17 +54.9% | 15.3% | SEK 16.00 | SEK 11.50 | n/a | 3 |
Jul ’25 | SEK 9.26 | SEK 13.17 +42.2% | 15.3% | SEK 16.00 | SEK 11.50 | n/a | 3 |
Jun ’25 | SEK 9.54 | SEK 13.17 +38.0% | 15.3% | SEK 16.00 | SEK 11.50 | n/a | 3 |
Apr ’25 | SEK 10.10 | SEK 13.75 +36.1% | 15.1% | SEK 16.00 | SEK 11.00 | n/a | 4 |
Mar ’25 | SEK 8.92 | SEK 13.75 +54.1% | 15.1% | SEK 16.00 | SEK 11.00 | n/a | 4 |
Feb ’25 | SEK 8.92 | SEK 13.63 +52.7% | 13.1% | SEK 15.50 | SEK 11.00 | n/a | 4 |
Nov ’24 | SEK 5.80 | SEK 14.50 +150.0% | 12.3% | SEK 16.00 | SEK 12.00 | n/a | 3 |
Oct ’24 | SEK 6.46 | SEK 14.50 +124.5% | 12.3% | SEK 16.00 | SEK 12.00 | n/a | 3 |
Sep ’24 | SEK 5.54 | SEK 13.17 +137.7% | 14.0% | SEK 15.50 | SEK 11.00 | n/a | 3 |
Nov ’23 | SEK 4.10 | SEK 13.17 +221.5% | 19.9% | SEK 15.50 | SEK 9.50 | SEK 5.80 | 3 |
Oct ’23 | SEK 3.49 | SEK 13.17 +277.8% | 19.9% | SEK 15.50 | SEK 9.50 | SEK 6.46 | 3 |
Sep ’23 | SEK 4.01 | SEK 13.17 +228.8% | 19.9% | SEK 15.50 | SEK 9.50 | SEK 5.54 | 3 |
Aug ’23 | SEK 4.16 | SEK 13.17 +216.5% | 19.9% | SEK 15.50 | SEK 9.50 | SEK 6.06 | 3 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.